|Day Low/High||1.66 / 1.70|
|52 Wk Low/High||0.71 / 2.18|
Pluristem's PLX-R18 is being studied by NIAID for Acute Radiation Syndrome (ARS), and following pharmacodynamics, safety and efficacy trials, the company plans to initiate a pivotal study to gain approval for ARS via the FDA Animal Rule.
IP addresses both 3D growth of placental and fat cells and the use of placental cells grown with 3D technology for the treatment of hematopoietic disorders
Second Hematologic Indication Being Developed in the U.S. for PLX-R18
Strong Balance Sheet, Two Active Clinical Development Programs in the U.S. Accelerated Pathways to Commercialization in Japan & Europe
Pluristem Therapeutics (PSTI) stock is popping in mid-morning trading on Thursday after the FDA granted an orphan drug designation to its preeclampsia treatment.
PLX Cells Were Demonstrated to be Safe for Both the Mother and Fetus and Improved Several Parameters of Preeclampsia in Several Animal Studies
Yaky Yanay to Deliver Two Presentations Regarding Accelerated Clinical Development Pathways in Europe and Japan
Effects of PLX-R18 Will Be Studied in the Lungs, Gastrointestinal Tract, Skin, and Bone Marrow Following Exposure to Catastrophic Levels of Radiation
Data Show the Mechanism of Action by Which PLX-R18 Treats Radiation-Induced Bone Marrow Damage
BioEurope 2015, EU Advanced Therapies Investor Day & Berlin Dialogue
ARM is the Preeminent Global Advocate for the Advancement of Regenerative Medicine
PLX-R18 for Use in Acute Radiation Syndrome (ARS) is Being Developed Under the Animal Rule Regulatory Pathway With the NIAID's Support